Lupin gets EIR from USFDA for its Nagpur facility
New Delhi: Drug firm Lupin Monday said it has received an establishment inspection report(EIR) from the US health regulator post the inspection of its Nagpur facility. "The United States Food and Drug Administration (USFDA) conducted a pre-approval inspection for its Phenytoin Sodium Extended-Release 100 mg capsules," Lupin said in a filing to BSE.
The plant was inspected by USFDA in September 2018, the company added.
USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.
Commenting on the development, Lupin MD Nilesh Gupta said: "The successful completion of the Nagpur facility inspection is a positive development as we continue our journey to meet and exceed international regulatory standards."
Shares of Lupin were today trading 1.64 per cent higher at Rs 868.20 apiece on BSE.
Read Also: Lupin gets EIR from USFDA for Nagpur facility
The plant was inspected by USFDA in September 2018, the company added.
USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.
Commenting on the development, Lupin MD Nilesh Gupta said: "The successful completion of the Nagpur facility inspection is a positive development as we continue our journey to meet and exceed international regulatory standards."
Shares of Lupin were today trading 1.64 per cent higher at Rs 868.20 apiece on BSE.
Read Also: Lupin gets EIR from USFDA for Nagpur facility
Next Story
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd